Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001193125-26-095014
Filing Date
2026-03-06
Accepted
2026-03-06 08:01:20
Documents
84
Period of Report
2025-12-31

Document Format Files

Seq Description Document Type Size
1 10-K pmvp-20251231.htm   iXBRL 10-K 3510869
2 EX-10.11 pmvp-ex10_11.htm EX-10.11 32222
3 EX-10.19 pmvp-ex10_19.htm EX-10.19 78431
4 EX-23.1 pmvp-ex23_1.htm EX-23.1 9031
5 EX-31.1 pmvp-ex31_1.htm EX-31.1 20636
6 EX-31.2 pmvp-ex31_2.htm EX-31.2 20428
7 EX-32.1 pmvp-ex32_1.htm EX-32.1 12318
8 EX-32.2 pmvp-ex32_2.htm EX-32.2 12881
9 GRAPHIC img60301129_0.jpg GRAPHIC 81287
10 GRAPHIC img60301129_1.jpg GRAPHIC 81287
11 GRAPHIC img60301129_2.jpg GRAPHIC 111464
  Complete submission text file 0001193125-26-095014.txt   13142643

Data Files

Seq Description Document Type Size
12 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT pmvp-20251231.xsd EX-101.SCH 1399443
87 EXTRACTED XBRL INSTANCE DOCUMENT pmvp-20251231_htm.xml XML 2340427
Mailing Address 400 ALEXANDER PARK DRIVE SUITE 301 PRINCETON NJ 08540
Business Address 400 ALEXANDER PARK DRIVE SUITE 301 PRINCETON NJ 08540 (609) 642-6670
PMV Pharmaceuticals, Inc. (Filer) CIK: 0001699382 (see all company filings)

EIN.: 463218129 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-39539 | Film No.: 26728498
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)